BRPI0916489A2 - particula tipo vírus (vlp), polinucleotídeo isolado, vetor de expressão, célula procariótica ou eucariótica, composição imunogênica, vacina, método para indução de uma resposta imune contra de chikungunya em um indivíduo e uso de uma partícula tipo vírus - Google Patents
particula tipo vírus (vlp), polinucleotídeo isolado, vetor de expressão, célula procariótica ou eucariótica, composição imunogênica, vacina, método para indução de uma resposta imune contra de chikungunya em um indivíduo e uso de uma partícula tipo vírusInfo
- Publication number
- BRPI0916489A2 BRPI0916489A2 BRPI0916489A BRPI0916489A BRPI0916489A2 BR PI0916489 A2 BRPI0916489 A2 BR PI0916489A2 BR PI0916489 A BRPI0916489 A BR PI0916489A BR PI0916489 A BRPI0916489 A BR PI0916489A BR PI0916489 A2 BRPI0916489 A2 BR PI0916489A2
- Authority
- BR
- Brazil
- Prior art keywords
- virus particle
- chikungunya
- vlp
- prokaryotic
- vaccine
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 2
- 239000002245 particle Substances 0.000 title 2
- 201000009182 Chikungunya Diseases 0.000 title 1
- 210000003527 eukaryotic cell Anatomy 0.000 title 1
- 239000013604 expression vector Substances 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
- 210000001236 prokaryotic cell Anatomy 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11820608P | 2008-11-26 | 2008-11-26 | |
| US61/118,206 | 2008-11-26 | ||
| US20111808P | 2008-12-05 | 2008-12-05 | |
| US61/201,118 | 2008-12-05 | ||
| PCT/US2009/006294 WO2010062396A2 (en) | 2008-11-26 | 2009-11-24 | Virus like particle compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0916489A2 true BRPI0916489A2 (pt) | 2018-02-06 |
| BRPI0916489B1 BRPI0916489B1 (pt) | 2021-11-09 |
Family
ID=42226306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0916489-8A BRPI0916489B1 (pt) | 2008-11-26 | 2009-11-24 | Partícula do tipo vírus (vlp), composição imunogênica, vacina e uso |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US9353353B2 (pt) |
| EP (2) | EP2370455B1 (pt) |
| CN (2) | CN107574156A (pt) |
| AU (1) | AU2009320287B2 (pt) |
| BR (1) | BRPI0916489B1 (pt) |
| MY (1) | MY161495A (pt) |
| SG (1) | SG171828A1 (pt) |
| WO (1) | WO2010062396A2 (pt) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2720166A1 (en) * | 2008-04-04 | 2009-10-08 | David B. Weiner | Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same |
| EP2370455B1 (en) | 2008-11-26 | 2019-07-03 | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Virus like particle compositions and methods of use |
| WO2012095542A1 (es) | 2011-01-10 | 2012-07-19 | Siesta Systems, S.A. | Dispositivo de apoyo parieto-occipital para sujeción lateral de la cabeza en camas con el respaldo elevado |
| US9487563B2 (en) | 2011-01-31 | 2016-11-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Virus-like particles and methods of use |
| WO2012130723A1 (en) | 2011-03-25 | 2012-10-04 | Intervet International B.V. | Salmonid alphavirus vaccine |
| EP2720715B1 (en) | 2011-06-17 | 2017-08-09 | Bharat Biotech International Limited | Vaccine composition comprising an inactivated chikungunya virus strain |
| KR102181258B1 (ko) * | 2012-02-16 | 2020-11-20 | 브이엘피 테라퓨틱스 엘엘씨 | 바이러스 유사 입자 조성물 |
| DK178233B1 (en) * | 2012-09-17 | 2015-09-14 | Novartis Tiergesundheit Ag | Fiskevaccine |
| EP2712871A1 (en) * | 2012-09-27 | 2014-04-02 | Institut Pasteur | Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications |
| BR112015006840A2 (pt) * | 2012-09-27 | 2017-11-21 | Res Found Dev | vírus chikungunya atenuado |
| SG10201709917VA (en) * | 2013-06-03 | 2017-12-28 | Vlp Therapeutics Llc | Malaria vaccine |
| TWI676636B (zh) * | 2013-07-12 | 2019-11-11 | Ｖｌｐ醫療股份有限公司 | 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 |
| CA2942706C (en) | 2014-03-28 | 2020-01-14 | Tamir Biotechnology, Inc. | Rnase for use in treating or preventing viral infections |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| US9969986B2 (en) * | 2014-08-08 | 2018-05-15 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| US9642794B2 (en) | 2014-08-18 | 2017-05-09 | Tamir Biotechnology, Inc. | Antiviral pharmaceutical for topical administration |
| KR102532832B1 (ko) | 2014-09-11 | 2023-05-16 | 브이엘피 테라퓨틱스 인코포레이티드 | 플라비바이러스 바이러스 유사 입자 |
| SG10201911292SA (en) | 2015-06-15 | 2020-02-27 | Tamir Biotechnology Inc | Pharmaceuticals for treatment of viral infections of the eye |
| US10166281B2 (en) * | 2015-09-04 | 2019-01-01 | Vlp Therapeutics, Llc | Method and composition for modulating immune response |
| ES2973267T3 (es) | 2015-12-23 | 2024-06-19 | Valneva Se | Purificación de virus |
| WO2017142807A1 (en) | 2016-02-16 | 2017-08-24 | Tamir Biotechnology, Inc. | Treatment or prevention of zika virus infections by administration of a ribonuclease |
| EP3634449A4 (en) | 2017-05-08 | 2021-03-17 | Gritstone Oncology, Inc. | ALPHAVIRUS NEOANTIGEN VECTORS |
| WO2019016756A1 (en) * | 2017-07-21 | 2019-01-24 | Glaxosmithkline Biologicals Sa | ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES |
| JP7301811B2 (ja) | 2017-09-21 | 2023-07-03 | ヴァルネヴァ エスイー | 免疫原性チクングニアウイルスｃｈｉｋｖ－ｄｅｌｔａ ５ｎｓｐ３を含む医薬組成物を製造する方法 |
| SG11202005792RA (en) | 2017-12-20 | 2020-07-29 | Vlp Therapeutics Llc | Alphavirus replicon particle |
| MX2020007077A (es) | 2018-01-04 | 2020-10-28 | Iconic Therapeutics Inc | Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados. |
| US12448415B2 (en) | 2018-01-04 | 2025-10-21 | Washington University | Compositions and methods for inhibition of alphavirus infection |
| WO2020069054A1 (en) * | 2018-09-27 | 2020-04-02 | Texas Tech University System | Stable cell line secreting chikungunya virus (chikv) virus like particles (vlp) for vaccines |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| PH12022550939A1 (en) * | 2019-10-25 | 2024-02-12 | Bavarian Nordic As | Chikungunya virus-like particle vaccine and methods of using the same |
| TWI891771B (zh) | 2020-04-17 | 2025-08-01 | 美商Ｖｌｐ醫療股份有限公司 | 冠狀病毒疫苗 |
| AU2021264216A1 (en) | 2020-04-30 | 2022-11-10 | Vlp Therapeutics, Inc. | Cytokine immunotherapy |
| CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
| EP4326858A4 (en) * | 2021-04-23 | 2025-03-12 | VLP Therapeutics, Inc. | GALECTIN-TARGETED IMMUNOTHERAPY |
| CN116286983A (zh) * | 2023-01-18 | 2023-06-23 | 中国科学院深圳先进技术研究院 | 表达il-7的sinv载体及其在制备抗肿瘤药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| CA2776391C (en) | 2001-10-01 | 2015-03-31 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
| US20040121465A1 (en) | 2002-02-14 | 2004-06-24 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
| US9045727B2 (en) * | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| WO2005034992A2 (en) | 2003-09-15 | 2005-04-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv vaccines based on env of multiple clades of hif |
| EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
| US20100233209A1 (en) * | 2005-08-11 | 2010-09-16 | Higgs Stephen T | Chikungunya virus infectious clones and uses therefor |
| CN101516395B (zh) | 2006-09-01 | 2014-03-26 | 伯哈拉特生物技术国际有限公司 | 抗屈曲病毒感染的疫苗 |
| EP2370455B1 (en) | 2008-11-26 | 2019-07-03 | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Virus like particle compositions and methods of use |
-
2009
- 2009-11-24 EP EP09829477.0A patent/EP2370455B1/en active Active
- 2009-11-24 AU AU2009320287A patent/AU2009320287B2/en active Active
- 2009-11-24 EP EP19183770.7A patent/EP3613761A1/en active Pending
- 2009-11-24 US US13/131,287 patent/US9353353B2/en active Active
- 2009-11-24 CN CN201710200081.3A patent/CN107574156A/zh active Pending
- 2009-11-24 MY MYPI2011002376A patent/MY161495A/en unknown
- 2009-11-24 SG SG2011038262A patent/SG171828A1/en unknown
- 2009-11-24 BR BRPI0916489-8A patent/BRPI0916489B1/pt active IP Right Grant
- 2009-11-24 CN CN200980155476XA patent/CN102317308A/zh active Pending
- 2009-11-24 WO PCT/US2009/006294 patent/WO2010062396A2/en not_active Ceased
-
2016
- 2016-05-03 US US15/145,483 patent/US10369208B2/en active Active
-
2019
- 2019-07-23 US US16/520,113 patent/US11369674B2/en active Active
-
2022
- 2022-06-27 US US17/850,706 patent/US11992523B2/en active Active
-
2024
- 2024-05-27 US US18/675,059 patent/US12281336B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20240307520A1 (en) | 2024-09-19 |
| US11369674B2 (en) | 2022-06-28 |
| BRPI0916489B1 (pt) | 2021-11-09 |
| US20120003266A1 (en) | 2012-01-05 |
| US9353353B2 (en) | 2016-05-31 |
| CN107574156A (zh) | 2018-01-12 |
| US20230025038A1 (en) | 2023-01-26 |
| AU2009320287A1 (en) | 2011-06-30 |
| US12281336B2 (en) | 2025-04-22 |
| MY161495A (en) | 2017-04-14 |
| AU2009320287B2 (en) | 2015-10-08 |
| US11992523B2 (en) | 2024-05-28 |
| WO2010062396A3 (en) | 2010-12-09 |
| SG171828A1 (en) | 2011-07-28 |
| EP2370455A2 (en) | 2011-10-05 |
| US20160303221A1 (en) | 2016-10-20 |
| EP2370455A4 (en) | 2012-07-04 |
| EP3613761A1 (en) | 2020-02-26 |
| WO2010062396A2 (en) | 2010-06-03 |
| US20200085938A1 (en) | 2020-03-19 |
| CN102317308A (zh) | 2012-01-11 |
| EP2370455B1 (en) | 2019-07-03 |
| US10369208B2 (en) | 2019-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0916489A2 (pt) | particula tipo vírus (vlp), polinucleotídeo isolado, vetor de expressão, célula procariótica ou eucariótica, composição imunogênica, vacina, método para indução de uma resposta imune contra de chikungunya em um indivíduo e uso de uma partícula tipo vírus | |
| BRPI1012811A2 (pt) | vacinas contra o vírus herpes simplex tipo 2: composições e métodos para obtenção de uma resposta imune | |
| BR112013030321A2 (pt) | composição de vacina, método para preparar a composição de vacina, uso da composição de vacina, método para imunizar um porco, cepa de vacina contra csfv e uso de uma célula no cultivo de uma cepa de vacina contra csfv. | |
| WO2011103453A3 (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease | |
| WO2016073955A3 (en) | Cells lacking b2m surface expression and methods for allogeneic administration of such cells | |
| WO2011005799A3 (en) | Rna containing modified nucleotides and use thereof in vaccines | |
| CN106715699A8 (zh) | 用于减弱抗病毒转移载体免疫应答的方法和组合物 | |
| DK3310909T3 (da) | Sammensætninger og fremgangsmåder til at føre proteiner til specifikke loci i genomet | |
| SG11202011817WA (en) | Compositions and methods to promote host defense and stimulate, expand, and/or reset t cell repertoires | |
| BRPI1007721A2 (pt) | composição de vacina para induzir uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolada e método para induzir uma resposta imunológica para um rotavírus em um indivíduo | |
| HUE069586T2 (hu) | Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása | |
| BR112012019757A2 (pt) | composição imunogênica, e, método para induzir uma resposta imune a um polissacarídeo capsular | |
| MX2023006203A (es) | Vacunas novedosas contra el virus de zika. | |
| BR112012008790A2 (pt) | sequências de polinucleotídeos, vetor, proteína de fusão, método de produção de uma proteína de fusão, célula hospedeira, composição imunogênica, método de estímulo ou indução de reação imunológica e usos de uma sequência de polinucleotídeos, de um vetor, de uma proteína de fusão ou de uma composição imunogênica | |
| WO2011163628A3 (en) | Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof | |
| BR112013030395A2 (pt) | polipeptídeo, polinucleotídeo, vetor, composição imunogênica, vacina, e, uso de uma composição imunogênica | |
| CO2017007105A2 (es) | Nuevos virus de tilapia | |
| PL2658570T3 (pl) | Sposoby i kompozycje szczepionki przeciwko wirusowi wirusowej biegunki bydła typu 1b | |
| SG11201610731VA (en) | A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection | |
| Stambas et al. | Killer T cells in influenza | |
| MX377258B (es) | Composiciones de vectores poxvirus y su uso para inducir una respuesta inmunitaria. | |
| HRP20210031T1 (hr) | Pripravci i metode mutantskog faktora viii | |
| BRPI0820258A2 (pt) | composto, composições de vacina e farmacêutica, e , métodos para estimular uma resposta imune em um indivíduo e para tratar um indivíduo | |
| WO2011057254A3 (en) | Simian adenoviral vector-based vaccines | |
| EP2643014A4 (en) | HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B12F | Other appeals [chapter 12.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |